TY - JOUR
T1 - Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis
T2 - Two-year results from a Phase III double-blind, randomized controlled trial
AU - Krasowska, D.
AU - Gambichler, T.
AU - Cortés, C.
AU - Horev, A.
AU - Compagno, N.
AU - Dahale, S. S.
AU - Papanastasiou, P.
AU - Keefe, D.
N1 - Funding Information:
The authors thank Rajib Kishore Hazam, Avinash Thakur, Rabi Panigrahy, Yugandhar Vudhya Gowrisankar and Asma S (Novartis) for editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).
Publisher Copyright:
© 2023 European Academy of Dermatology and Venereology.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Background: Secukinumab has previously demonstrated sustained efficacy and favourable safety for up to 52 weeks in paediatric patients (children and adolescents aged 6 to <18 years) with severe chronic plaque psoriasis (NCT02471144). Objective: To investigate the long-term (104 weeks) efficacy and safety of secukinumab. Methods: After 52 weeks, patients continued to receive secukinumab low dose (LD [75/150 mg]) or high dose (HD [75/150/300 mg]). Patients on etanercept (0.8 mg/kg) until Week 52 entered follow-up. Data for patients receiving secukinumab LD from the beginning and those switching to secukinumab LD from placebo (‘Any secukinumab’ LD) and patients receiving secukinumab HD from the beginning and those switching to secukinumab HD from placebo (‘Any secukinumab’ HD) are presented. Assessments: Psoriasis Area and Severity Index (PASI) score, PASI (75/90/100) responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, Children's Dermatology Life Quality Index (CDLQI) score and CDLQI 0/1 response up to Week 104, and, safety up to Week 104 for all patients and up to 4 years for some patients (~320 patient-years [PY] of treatment). Results: Secukinumab-treated patients showed sustained PASI 75/90/100 and IGA mod 2011 0/1 responses up to Week 104. Throughout the second year of treatment, efficacy was similar for the ‘Any secukinumab’ LD and HD groups for PASI 75 and IGA mod 2011 0/1 responses. PASI 90/100 responses were mostly comparable between the dose groups up to Week 88, but higher in the ‘Any secukinumab’ HD than the ‘Any secukinumab’ LD group at Week 104. Patients achieved a sustained CDLQI 0/1 response that was similar between the ‘Any secukinumab’ LD (61.1%) and HD (65.0%) groups. Safety data were consistent with the established safety profile of secukinumab. Conclusion: Secukinumab demonstrated sustained long-term efficacy (up to 2 years) and a favourable safety profile (~320 PY of treatment) in paediatric patients with severe chronic plaque psoriasis.
AB - Background: Secukinumab has previously demonstrated sustained efficacy and favourable safety for up to 52 weeks in paediatric patients (children and adolescents aged 6 to <18 years) with severe chronic plaque psoriasis (NCT02471144). Objective: To investigate the long-term (104 weeks) efficacy and safety of secukinumab. Methods: After 52 weeks, patients continued to receive secukinumab low dose (LD [75/150 mg]) or high dose (HD [75/150/300 mg]). Patients on etanercept (0.8 mg/kg) until Week 52 entered follow-up. Data for patients receiving secukinumab LD from the beginning and those switching to secukinumab LD from placebo (‘Any secukinumab’ LD) and patients receiving secukinumab HD from the beginning and those switching to secukinumab HD from placebo (‘Any secukinumab’ HD) are presented. Assessments: Psoriasis Area and Severity Index (PASI) score, PASI (75/90/100) responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, Children's Dermatology Life Quality Index (CDLQI) score and CDLQI 0/1 response up to Week 104, and, safety up to Week 104 for all patients and up to 4 years for some patients (~320 patient-years [PY] of treatment). Results: Secukinumab-treated patients showed sustained PASI 75/90/100 and IGA mod 2011 0/1 responses up to Week 104. Throughout the second year of treatment, efficacy was similar for the ‘Any secukinumab’ LD and HD groups for PASI 75 and IGA mod 2011 0/1 responses. PASI 90/100 responses were mostly comparable between the dose groups up to Week 88, but higher in the ‘Any secukinumab’ HD than the ‘Any secukinumab’ LD group at Week 104. Patients achieved a sustained CDLQI 0/1 response that was similar between the ‘Any secukinumab’ LD (61.1%) and HD (65.0%) groups. Safety data were consistent with the established safety profile of secukinumab. Conclusion: Secukinumab demonstrated sustained long-term efficacy (up to 2 years) and a favourable safety profile (~320 PY of treatment) in paediatric patients with severe chronic plaque psoriasis.
UR - http://www.scopus.com/inward/record.url?scp=85152295456&partnerID=8YFLogxK
U2 - 10.1111/jdv.19063
DO - 10.1111/jdv.19063
M3 - Article
C2 - 36971771
AN - SCOPUS:85152295456
SN - 0926-9959
VL - 37
SP - 1616
EP - 1625
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 8
ER -
